HRP20240037T1 - Car t-stanice prema bcma za liječenje multiplog mijeloma - Google Patents
Car t-stanice prema bcma za liječenje multiplog mijeloma Download PDFInfo
- Publication number
- HRP20240037T1 HRP20240037T1 HRP20240037TT HRP20240037T HRP20240037T1 HR P20240037 T1 HRP20240037 T1 HR P20240037T1 HR P20240037T T HRP20240037T T HR P20240037TT HR P20240037 T HRP20240037 T HR P20240037T HR P20240037 T1 HRP20240037 T1 HR P20240037T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell
- car
- seq
- domain
- treatment
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 2
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Himerni antigenski receptor (CAR) naznačen time što sadrži:
a. jednolančani varijabilni fragment "scFv" BCMA-ciljno djelujuću funkcionalnu grupu, koja sadrži VL domenu i VH domenu, pri čemu navedene VH i VL domene respektivno sadrže SEQ ID NO 1 i 2;
b. transmembranska domena vezana za domenu zgloba koji sadrži SEQ ID NO: 9;
c. kostimulatorna signalna domena koja sadrži SEQ ID NO: 11; i
d. unutarstanična signalna domena koja sadrži SEQ ID NO: 10.
2. Himerni antigenski receptor (CAR) prema patentnom zahtjevu 1, naznačen time što se CAR sastoji od SEQ ID NO: 13.
3. Nukleinska kiselina koja kodira CAR u skladu sa bilo kojim od patentnih zahtjeva 1 do 2.
4. Stanica naznačena time što sadrži nukleinsku kiselinu u skladu sa patentnim zahtjevom 3.
5. Stanica u skladu sa patentnim zahtjevom 4, naznačena time što je stanica T-stanica.
6. Farmaceutski pripravak naznačen time što sadrži mnoštvo stanica u skladu sa patentnim zahtjevom 5 i farmaceutski prihvatljiv nosač ili razrjeđivač.
7. Stanica u skladu sa patentnim zahtjevom 5 ili farmaceutski pripravak u skladu sa patentnim zahtjevom 6, za uporabu kao lijek.
8. Stanica u skladu sa patentnim zahtjevom 5 ili farmaceutski pripravak u skladu sa patentnim zahtjevom 6, za uporabu u postupku liječenja multiplog mijeloma, naznačeno time što postupak sadrži primjenu stanice ili pripravka pacijentu kojem je to potrebno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382673 | 2019-08-02 | ||
| EP20757544.0A EP4007777B1 (en) | 2019-08-02 | 2020-08-03 | Car t-cells against bcma for the treatment of multiple myeloma |
| PCT/EP2020/071831 WO2021023721A1 (en) | 2019-08-02 | 2020-08-03 | Car t-cells against bcma for the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240037T1 true HRP20240037T1 (hr) | 2024-03-29 |
Family
ID=67658496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240037TT HRP20240037T1 (hr) | 2019-08-02 | 2020-08-03 | Car t-stanice prema bcma za liječenje multiplog mijeloma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220267459A1 (hr) |
| EP (2) | EP4272837A3 (hr) |
| JP (1) | JP2022542443A (hr) |
| AU (1) | AU2020325690A1 (hr) |
| CA (1) | CA3148930A1 (hr) |
| DK (1) | DK4007777T3 (hr) |
| ES (1) | ES2971033T3 (hr) |
| FI (1) | FI4007777T3 (hr) |
| HR (1) | HRP20240037T1 (hr) |
| HU (1) | HUE064890T2 (hr) |
| LT (1) | LT4007777T (hr) |
| PL (1) | PL4007777T3 (hr) |
| PT (1) | PT4007777T (hr) |
| RS (1) | RS65094B1 (hr) |
| SI (1) | SI4007777T1 (hr) |
| WO (1) | WO2021023721A1 (hr) |
| ZA (1) | ZA202201166B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023152747A1 (en) * | 2022-02-09 | 2023-08-17 | Hadasit Medical Research Services And Development Ltd. | Anti-bcma car to target immune-related disorders, compositions and method thereof |
| EP4378953A1 (en) * | 2022-12-02 | 2024-06-05 | Universitat de Barcelona | Cd229 targeting moiety for the tratment of cd229 positive cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5674704A (en) | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
| US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
| CA3026778A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN108004259B (zh) * | 2016-11-02 | 2020-06-30 | 上海恒润达生生物科技有限公司 | 靶向b细胞成熟抗原的嵌合抗原受体及其用途 |
| CN108285489A (zh) * | 2017-01-09 | 2018-07-17 | 上海恒润达生生物科技有限公司 | 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途 |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| AU2018367896B2 (en) * | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
-
2020
- 2020-08-03 JP JP2022506455A patent/JP2022542443A/ja active Pending
- 2020-08-03 DK DK20757544.0T patent/DK4007777T3/da active
- 2020-08-03 EP EP23190869.0A patent/EP4272837A3/en active Pending
- 2020-08-03 SI SI202030350T patent/SI4007777T1/sl unknown
- 2020-08-03 LT LTEPPCT/EP2020/071831T patent/LT4007777T/lt unknown
- 2020-08-03 CA CA3148930A patent/CA3148930A1/en active Pending
- 2020-08-03 AU AU2020325690A patent/AU2020325690A1/en active Pending
- 2020-08-03 FI FIEP20757544.0T patent/FI4007777T3/fi active
- 2020-08-03 ES ES20757544T patent/ES2971033T3/es active Active
- 2020-08-03 RS RS20240043A patent/RS65094B1/sr unknown
- 2020-08-03 US US17/632,191 patent/US20220267459A1/en active Pending
- 2020-08-03 PL PL20757544.0T patent/PL4007777T3/pl unknown
- 2020-08-03 WO PCT/EP2020/071831 patent/WO2021023721A1/en active Application Filing
- 2020-08-03 EP EP20757544.0A patent/EP4007777B1/en active Active
- 2020-08-03 HU HUE20757544A patent/HUE064890T2/hu unknown
- 2020-08-03 HR HRP20240037TT patent/HRP20240037T1/hr unknown
- 2020-08-03 PT PT207575440T patent/PT4007777T/pt unknown
-
2022
- 2022-01-25 ZA ZA2022/01166A patent/ZA202201166B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4007777T3 (da) | 2024-01-15 |
| AU2020325690A1 (en) | 2022-03-03 |
| PL4007777T3 (pl) | 2024-03-11 |
| EP4272837A2 (en) | 2023-11-08 |
| JP2022542443A (ja) | 2022-10-03 |
| SI4007777T1 (sl) | 2024-03-29 |
| EP4007777A1 (en) | 2022-06-08 |
| EP4272837A3 (en) | 2024-02-28 |
| US20220267459A1 (en) | 2022-08-25 |
| CA3148930A1 (en) | 2021-02-11 |
| EP4007777B1 (en) | 2023-10-11 |
| RS65094B1 (sr) | 2024-02-29 |
| FI4007777T3 (fi) | 2024-01-11 |
| PT4007777T (pt) | 2024-01-12 |
| HUE064890T2 (hu) | 2024-04-28 |
| ZA202201166B (en) | 2022-10-26 |
| WO2021023721A1 (en) | 2021-02-11 |
| LT4007777T (lt) | 2024-02-12 |
| ES2971033T3 (es) | 2024-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| Fu et al. | A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve | |
| JP2024023302A (ja) | Ｔｉｍ３に対する抗体およびその使用 | |
| ES2662519T3 (es) | Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos | |
| HRP20180027T1 (hr) | Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv) | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| Guo et al. | Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| HRP20240037T1 (hr) | Car t-stanice prema bcma za liječenje multiplog mijeloma | |
| US11370830B2 (en) | Neutralizing antibodies that bind to the zika virus domain III envelope region | |
| US12024554B2 (en) | Compositions and methods for treating HIV/AIDS with immunotherapy | |
| AU2022202819A1 (en) | Antibody-mediated neutralization of Chikungunya virus | |
| Ferrara et al. | Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections | |
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| CN107108721B (zh) | 包含hiv-1包膜靶向臂的双特异性分子 | |
| JP2013121353A5 (hr) | ||
| CN104955847A (zh) | HIV-1 Env结合抗体、融合蛋白及其使用方法 | |
| TW200925279A (en) | Methods for recombinant manufacturing of anti-RSV antibodies | |
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| JP2017530092A5 (hr) | ||
| EP4013797A1 (en) | Multispecific antigen-binding molecules for cell targeting and uses thereof | |
| Yuan et al. | A bispecific antibody targeting RBD and S2 potently neutralizes SARS-CoV-2 Omicron and other variants of concern | |
| EP3778630A1 (en) | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region | |
| CA3179348A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |